$ Value
$91K
Shares
11,143
Price
$8
Filed
May 20
Insider
Name
Calkins Daniel
Title
Chief Financial Officer
CIK
0001951861
Roles
Transaction Details
Transaction Date
2025-05-20
Code
S
Table
Non-Derivative
Ownership
Direct
Equity Swap
No
Shares After
114,055
Footnotes
The reported securities were subject to a performance RSU award that was granted on June 18, 2024. 150,000 RSUs vested on May 16, 2025, upon the Issuer's Compensation Committee of the board of directors determining the performance criteria of approval by the FDA of an NDA for the Company's combination therapy of avutometinib and defactinib for the treatment of low-grade serous ovarian cancer had occurred. | The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units.
Filing Info
Calkins Daniel's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-03-20 | VSTM | A | $327 |
| 2026-01-21 | VSTM | A | $0 |
| 2026-01-12 | VSTM | ▼ | $36K |
| 2025-12-24 | VSTM | ▼ | $629 |
| 2025-09-24 | VSTM | ▼ | $231 |
| 2025-09-22 | VSTM | ▼ | $518 |
| 2025-06-23 | VSTM | ▼ | $118 |
| 2025-06-20 | VSTM | ▼ | $21K |
| 2025-05-20 | VSTM | ▼ | $91K |
| 2025-05-16 | VSTM | A | $0 |
Other Insiders at VSTM (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
|
Paterson Dan
President and CEO
|
— | $6K | 2026-02-04 |
|
Calkins Daniel
Chief Financial Officer
|
— | — | 2026-03-20 |